II型骨盆肿瘤切除后体外辐照自体骨复合全髋关节置换重建可行但并发症多
这项来自单一骨肿瘤专科的回顾性病例系列评估了2005年1月至2022年1月间48例II型骨盆切除患者中24例接受体外辐照自体骨复合全髋关节置换重建者的结局,最终16例纳入分析。72个月无部分或全部移植物取出生存率为50%(95%CI 26%至75%),中位MSTS评分18分(范围6至25),16例中15例发生17项并发症,其中16项为主要并发症。作者认为该技术可行,但并发症和再手术常见。
要点
- 72个月无移植物取出生存率为50%(95%CI 26%至75%),末次随访时8例移植物得以保留。
- 末次随访中位MSTS评分为18分(范围6至25),满分30分。
- 16例中15例发生17项并发症,其中16项为主要并发症,14例接受了21次非计划再手术。
核心结论
- 体外辐照自体骨复合全髋关节置换是II型骨盆切除后可行的重建技术,但并发症和再手术常见。
- 作者认为,尽管尚无重建技术被证明优于其他替代方案,选择可能的重建方法时应考虑该技术相关的高并发症和再手术风险。
研究设计与样本
- 这是一项来自单一骨肿瘤专科单元的回顾性病例系列,评估2005年1月至2022年1月间由三位外科医生治疗的48例II型骨盆切除患者。
- 48例中50%(24/48)接受股骨和髋臼重建即体外辐照自体骨复合全髋关节置换,其中21%(5/24)在2年前失访、13%(3/24)在2年内死亡且重建完整,最终67%(16/24)纳入分析。
- 16例中12例为男性,平均年龄38±21岁;肿瘤类型包括软骨肉瘤8例、恶性间叶肿瘤4例、骨肉瘤2例和尤文肉瘤2例。
- 采用Kaplan-Meier法计算72个月无全部或部分移植物取出生存率,末次随访时使用肌肉骨骼肿瘤学会(MSTS)评分评估功能。
主要发现
- 初始重建后72个月无部分或全部移植物取出的生存率为50%(95%CI 26%至75%)。
- Kaplan-Meier分析显示估计平均移植物取出时间为43个月(95%CI 28至58)。
- 末次随访放射片上8例移植物得以保留。
- 末次随访中位MSTS评分为18分(范围6至25),满分30分,该评分包括已取出移植物的患者。
- 16例中15例发生17项并发症,其中16项为主要并发症;15例中14例接受一次或多次二次手术,共21次非计划额外手术;深部感染8例、假体脱位4例、无菌性髋臼组件松动3例、移植物骨折2例、异位骨化1例。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Malignancies involving the pelvic ring present numerous challenges, especially in the periacetabular area. Extensive resection of the pelvic region without reconstruction can lead to severe functional impairment. Numerous reconstructive options exist, but all have drawbacks. Extracorporeally irradiated autografts are one option for reconstruction after periacetabular resections; they offer the potential advantages of eliminating the risk of allogeneic reactions associated with allografts and preserving local anatomy. However, little is known about the durability and risks of this approach in pelvic reconstruction. QUESTIONS/PURPOSES: (1) What are the survival rates of the autograft used, and if there is graft loss, what is the extent of this loss? (2) What are the functional outcomes after the implementation of this method? (3) What is the rate and nature of complications associated with this approach? METHODS: This is a retrospective case series from one subspecialty tumor unit that evaluated patients treated between January 2005 to January 2022. During that time, three surgeons treated 48 patients with Type II resections (defined as resection of periacetabular area). Patients treated with isolated Type II resections were eligible, as were those treated either with Type I+II resections, Type II+III resections, Type I+II+III resections, and Type I+II+III+IV resections. Of those, 21% (10 of 48) were treated primarily with a cone prosthesis, 13% (6 of 48) were treated without femoral reconstruction, 10% (5 of 48) were treated with resection without reconstruction, and 6% (3 of 48) had a THA on the sacrum, leaving 50% (24 of 48) of patients who were treated with femoral and acetabular reconstruction using extracorporeally irradiated autograft and total hip replacement; those patients were potentially eligible for this study. During that time span, we used this approach in all Type II pelvic resection procedures, when a part of the hemipelvis could be preserved without resection (other than Type I+II+III+IV) and where we predicted that there would be sufficient bone stock after tumor removal. Of those, 21% (5 of 24) were lost to follow-up before 2 years, and 13% (3 of 24) died within 2 years with the reconstruction intact and without any reoperation or graft loss, leaving 67% (16 of 24) for analysis here. Demographic characteristics, type of tumor, tumor origin site, type of applied resection, and extent of applied surgical procedure were noted. Of 16 patients, 12 were male, with a mean age of 38 ± 21 years. Tumor types included chondrosarcoma in eight patients, malignant mesenchymal tumor in four patients, osteosarcoma in two patients, and Ewing sarcoma in two patients. Among these, 10 patients had tumors originating from the pelvis, whereas six patients had tumors originating from the proximal femur. We used a Kaplan-Meier estimator to calculate survivorship free from total or partial graft removal at 72 months. To measure functional results, the Musculoskeletal Tumor Society (MSTS) scoring system was utilized at most recent follow-up so as to be able to evaluate the impact of complications (if any) on the ultimate result. The MSTS score ranges from a minimum of 0 points to a maximum of 30 points, where a higher score reflects lower pain and higher functional and emotional capacity. Related complications, time of complications, secondary interventions, and mortality rates were also ascertained from chart review. RESULTS: Graft survival rate at 72 months after initial reconstruction, free from partial or total graft removal, was 50% (95% CI 26% to 75%). Kaplan-Meier analyses revealed estimated mean time of graft removal as 43 months (95% CI 28 to 58). The graft was protected in eight patients on their final follow-up radiographs. The median (range) MSTS score was 18 (6 to 25) of 30 points at most-recent follow-up (these scores include patients who have had their grafts removed). In all, 15 of 16 patients had 17 complications; 16 were major complications (defined as those substantial enough to result in further surgery or a life- or limb-threatening event). A total of 14 of those 15 patients underwent one or more secondary procedures (a total of 21 unplanned additional procedures were performed in those patients). Deep infection was the most common complication, occurring in eight patients. Prosthesis dislocation occurred in four patients. Three patients developed aseptic acetabular component loosening, two had graft fractures, and one patient developed heterotopic ossification. CONCLUSION: Composite reconstruction with extracorporeal irradiated autografts plus total hip replacement is a feasible reconstruction technique after Type II pelvic resections, although complications and reoperations were common. Although no reconstruction technique has been proven superior to other alternatives, the high risk of complications and reoperations associated with this technique should be considered when selecting from among possible alternative reconstruction methods. LEVEL OF EVIDENCE: Level IV, therapeutic study.
引用
- Vahabi A, Kaya H, Tosyalı HK, et al. Composite Reconstruction With Irradiated Autograft Plus Total Hip Replacement After Type II Pelvic Resections for Tumors Is Feasible but Fraught With Complications. Clin Orthop Relat Res. 2024. PMID: 38666740. doi:10.1097/CORR.0000000000003097
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。